WVE-007
Nucleic Acid Target: INHBE
Wave Life Sciences
Most recent annual filing: 2026-02-26
- WVE-N531 NDA filing2026WVE-N531 NDA filing, 2026, notable
- Corporate redomiciliation updatemid-2026Corporate redomiciliation update, mid-2026, routine
- WVE-006 FDA approval2H 2026WVE-006 FDA approval, 2H 2026, thesis-defining
- WVE-007 trial start2H 2026WVE-007 trial start, 2H 2026, notable
- WVE-008 filing2H 2026WVE-008 filing, 2H 2026, notable
- Company guidance updateAug 2026Company guidance update, Aug 2026, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (5 active programs)
WVE-006
Nucleic Acid Target: SERPINA1, ADAR
WVE-008
Nucleic Acid Target: PNPLA3
WVE-N531
Nucleic Acid Target: DMD exon 53
WVE-003
Nucleic Acid Target: mHTT, SNP3, HTT
Technology platforms
PRISM · GSK
Proprietary RNA medicines discovery and drug development platform combining stereochemistry-controlled oligonucleotide chemistry, multiple RNA-targeting modalities (RNAi/SpiNA, RNA editing/AIMers, antisense, splicing, bifunctional), and GalNAc or free-uptake delivery. Enables development of stereopure oligonucleotides for rare and common diseases including hepatic/metabolic, neuromuscular, and neurodegenerative diseases.
PRISM
Wave's proprietary RNA medicine discovery and development platform combining multiple modalities (RNAi via SpiNA and RNA editing via AIMers), chemistry innovation, and human genetics insights; focused on rare and common disorders including obesity, AATD, and PNPLA3 liver disease
SpiNA
Stereopure interfering Nucleic Acid — proprietary RNAi chemistry platform delivering improvements in potency, duration of activity, and Ago2 loading; focus areas include obesity, liver disease, and other extra-hepatic indications
AIMer
RNA editing platform using proprietary chemistry to achieve site-directed A-to-I RNA editing; focus areas include alpha-1 antitrypsin deficiency and liver disease
Biotech Distilled coverage (7)
- 2026-07-30 UPDATE: Wave Life Sciences (WVE) - The FDA Meeting Has a Season, and the CEO Has a Plan 🔒 Paid
- 2026-05-18 UPDATE: Wave Life Sciences (WVE) - The MZ Phenotype Is Real, And So Is the Dynamic Response
- 2026-04-30 UPDATE: Wave Life Sciences (WVE) - The Clock is Set for May 18 🔒 Paid
- 2026-04-17 UPDATE: Wave Life Sciences (WVE) - Redomiciling to Delaware 🔒 Paid
- 2026-04-05 UPDATE: Wave Life Sciences (WVE) - The Smart Money Just Faded the Retail Panic 🔒 Paid
- 2026-03-27 UPDATE: Wave Life Sciences (WVE) - The Receipts Are In on WVE-007... 🔒 Paid
- 2026-03-03 Wave Life Sciences (WVE) - Scientific Deep Dive for Lead and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.